GraceFinance · Source-backed public company research
Telix Pharmaceuticals Ltd (TLX)
Nasdaq · Manufacturing · Pharmaceutical Preparations
Research deepening · 3/4 core data layers currently established
What Telix Pharmaceuticals Ltd does
Unit (of 100%) Total (Corporate & BU) Mr. Smith (CFO) Global services: progress made for commercial launch readiness of Zircaix and Pixclara and RLS services teams integrated into Global Services. Substantial progress on SOX compliance, strategic procurement capability in place, but uplift continues into 2026. Below target 65.00% 62.50% Dr. Cade (CMO) Equal measure between the business unit outcomes for both Precision Medicine and Therapeutics. Therapeutics: significant progress has been made across the therapeutic portfolio, however some milestones have experienced delays into 2026. Precision Medicine: achieved Illuccix registration in multiple EU countries, US approval of Gozellix, and filing completed in China. Pixclara and Zircaix received complete response letters (CRLs) from the FDA, which impacted market authorization timelines.
Open the company story
The live GraceFinance page shows source-backed financial changes, management context, guidance, confirmed events, risks, and connected history only when the applicable evidence and relationships have been established. Missing research stays visible instead of being inferred.